Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELPIS
- Development stage
- Unknown
- Lead developer
- S-Evans Biosciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ELPIS is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by S-Evans Biosci (Huaxiayuan). It is specifically designed for the treatment of acute-on-chronic liver failure (ACLF), a life-threatening condition characterized by acute hepatic decompensation and intense systemic inflammation. ELPIS functions by leveraging the innate immunomodulatory and anti-inflammatory properties of mesenchymal stem cells to mitigate the systemic inflammatory response syndrome (SIRS) that drives multi-organ failure in ACLF. Additionally, the therapy promotes liver tissue repair through the secretion of paracrine factors that stimulate hepatocyte regeneration and inhibit apoptosis. The product received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) in 2021, marking a significant step in the clinical application of cell therapies for end-stage liver diseases.
- Brand names
- ELPIS
- Other names
- Human Umbilical Cord Mesenchymal Stem Cell InjectionUC-MSC Injection人脐带间充质干细胞注射液
Beyond the preview
Go deeper on ELPIS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELPIS.